RECEIVED CENTRAL FAX CENTER MAY 0 7 2007

REMARKS/ARGUMENTS

Reconsideration of this application and entry of the foregoing amendments are respectfully requested.

Claims 1, 2, 4, 6, 8 and 10-12 stand rejected under 35 USC 102(b) as allegedly being anticipated by Linton et al as evidenced by Reyes et al. Withdrawal of the rejection is submitted to be in order in view of the above-noted revision of the claims to make reference to a human patient. Linton et al's studies were conducted in mice and thus the claims are not anticipated. Reconsideration is requested.

Claims 1, 2, 4, 6, 8, 10 and 11 stand rejected under 35 USC 102(b) as allegedly being anticipated by Ishimori et al. Withdrawal of the rejection is submitted to be in order in view of the above-noted revision of the claims to refer to a human patient. As the Examiner appreciates, the studies of Ishimori et al were conducted in mice. Accordingly, reconsideration is requested.

Claims 1, 2, 4, 6, 8, 10 and 11 stand rejected under 35 USC 102(a) as allegedly being anticipated by Sakai et al. As above, withdrawal of the rejection is submitted to be in order in view of the above-noted revision of claim 1. Reconsideration is requested.

Claims 1, 2,4, 6, 8, 10 and 11 stand rejected under 35 USC 102(a) as allegedly being anticipated by Rauscher et al. The studies described are mouse studies that do not anticipate the invention as now claimed. Reconsideration is requested.

Claims 1, 2, 4, 6, 8 and 10-13 stand rejected under 35 USC 102(a) as allegedly being anticipated by Werner et al. The studies described are mouse studies and do not anticipate the claims as now presented. Reconsideration is requested.

NIXON VANDERHYE PC

Fax 703+816+4100

May 7 2007 06:45pm P011/011

GOLDSCHMIDT-CLERMONT et al Appl. No. 10/788,423 May 7, 2007

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Mary J. Wilson Reg. No. 32,955

MJW:tat

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100